Home » Pigmentation Disorders Treatment Market

Pigmentation Disorders Treatment Market By Treatment Type (Topical Drugs, Chemical Peels, Microdermabrasion, Phototherapy, Laser Therapy), By Disease Type (Melasma, Albinism, Vitiligo, Post-Inflammatory Hyperpigmentation, Others) – Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Price: $4999

Published: | Report ID: 9697 | Report Format : PDF

Industry Outlook

The pigmentation disorders treatment market is expected to reach US$ 9,649.9 million by 2026, up from US$ 5,311.5 million in 2017, with a compound annual growth rate (CAGR) of 6.9% from 2018 to 2026. The American Association for Pediatric Ophthalmology and Strabismus (AAPOS) claims that 1 in 17,000 people suffer from some form of albinism. Vitiligo is a lifelong condition, and there is no permanent cure; however, exposure to UVA and UVB phototherapy stimulates the growth of melanocytes on the skin patches and treats hypopigmentation to a certain extent. In the present scenario, pharmaceutical manufacturers are using topical creams in combinations such as adapalene/benzoyl peroxide and adapalene/clindamycin for the treatment of dark facial spots caused by acne vulgaris. Currently, imiquimod cream (MEDA Pharma GmbH & Co. KG) is in phase 3 clinical trials being tested for better clinical outcomes in the treatment of solar lentigos.

North America currently dominates the pigmentation disorders market on account of the growing incidence of melasma in pregnant women. The presence of major players and a well-developed healthcare infrastructure benefit patients suffering from post-inflammatory hyperpigmentation in North America. The pigmentation disorders treatment market is growing at a rapid pace in Asia Pacific on account of key drivers, such as the competition exerted by local manufacturers. The other factors promoting growth are supportive regulatory norms favoring the growth of topical drugs and a rise in per capita income.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Market Synopsis

The rising prevalence of skin hyperpigmentation will provide excellent growth opportunities for topical drugs.

In the current scenario, topical drugs are dominating the treatment type segment owing to better clinical outcomes in patients suffering from pigmentation disorders. The topical drugs commonly prescribed throughout the globe are azelaic acid, hydroquinone, L-ascorbic acid, etc. Chemical peels have gained prominence in the last two decades to treat facial hyperpigmentation disorders. They are effective in treating facial wrinkles caused by aging and harmful sunlight, improving the appearance of mild scars, and treating dark spots caused by acne. Dermabrasion has developed a niche market owing to its popularity in solving facial defects such as pox scars, accident scars, age spots, and dull skin. The growth of phototherapy and laser therapy for treating pigmentation disorders is being driven by an increase in per capita income and an improved lifestyle. However, the high costs associated with photo and laser therapy are a limitation to its market growth.

The increased incidence of melasma in postpartum women will result in double-digit growth.

Melasma, often known as chloasma, occurs in 90% of pregnant women. It results in discoloration of the skin in patches, usually on the forearms, chin, cheeks, bridge of the nose, and forehead. The incidence of melasma is higher in dark-skinned people in comparison to fair-skinned people. The chief factors responsible for the occurrence of melasma in women are hormones, pregnancy, and the use of birth control pills. Melasma results in huge demand for topical drugs, chemical peels, and microdermabrasion for dermal treatment. Post-inflammatory hyperpigmentation is set to register growth at a rapid pace due to key factors such as the increasing number of domestic accidents resulting in dermal burns and skin tissue abrasion, which result in hyperpigmentation due to excess melanin production during the healing process.

Increasing competition from local players in Asia-Pacific will result in tremendous growth during the forecast period.

North America controls 42% of the market and thus dominates the global market for pigmentation disorders treatment. The important parameters responsible for the burgeoning growth of North America are the presence of market leaders pioneering in dermatology products, such as Galderma S.A., RXi Pharmaceuticals Corporation, and Vivier Pharma. The rising number of patients suffering from skin pigmentation disorders due to harmful exposure to UV radiation and increasing public awareness related to skin diseases propels the pigmentation disorders treatment market’s growth in Europe. Asia Pacific is set to register faster growth owing to the competition created by local players. Increased per capita income and increased funding for research and development by pharmaceutical companies to improve the quality and efficacy of dermal products have a positive impact on the market’s growth in Asia Pacific.

Periods of History and Forecast

2016 : Historic year.

2017:Base Year

2018–2026: Forecast Period

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Report Scope by Segments

The quantitative analysis for the report on the pigmentation disorders treatment market is furnished on the basis of the latest market trends. The market segmentation comprises treatment type, disease type, and geography.

Treatment Type (2016-2026; US$ Million)

  • Topical Drugs
  • Chemical Peels
  • Microdermabrasion
  • Phototherapy
  • Laser Therapy
  • Disease Type (2016-2026; US$ Million)
  • Melasma
  • Albinism
  • Vitiligo
  • Post-Inflammatory Hyperpigmentation
  • Others (such as Solar Lentigines and Acne Vulgaris)

Geography Segment (2016-2026; millions of dollars)

North America

  • United States
  • Canada

Europe

  • United Kingdom
  • Germany

Rest of Europe

  • Asia-Pacific (APAC)
  • China
  • Japan
  • Rest of APAC

Latin America (LATAM)

  • Brazil
  • Mexico
  • rest of Latin America

Middle East and Africa (MEA)

  • GCC
  • Rest of the Middle East and Africa

A market assessment of the pigmentation disorders treatment market is performed in order to understand the current market trend and perform quantitative analysis. A product portfolio is helpful in giving valuable information about the medicines currently being used for the treatment of pigmentation disorders. The major players spearheading the pigmentation disorders treatment market are Allergan, Bayer AG, Galderma S.A., EpiPharm AG, Pierre Fabre Laboratories, La-Roche Posay, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals Corporation, SkinCeuticals, and Vivier Pharma.

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Pigmentation Disorders Treatment Market Portraiture
2.2. Global Pigmentation Disorders Treatment Market, by Treatment Type, 2017 (US$ Mn)
2.3. Global Pigmentation Disorders Treatment Market, by Disease Type, 2017 (US$ Mn)
2.4. Global Pigmentation Disorders Treatment Market, by Geography, 2017 (US$ Mn)

Chapter 3. Pigmentation Disorders Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Pigmentation Disorders Treatment Market, by Key Players, 2017

Chapter 4. Global Pigmentation Disorders Treatment Market, by Treatment Type
4.1. Overview
4.2. Topical Drugs
4.3. Chemical Peels
4.4. Microdermabrasion
4.5. Phototherapy
4.6. Laser Therapy

Chapter 5. Global Pigmentation Disorders Treatment Market, by Disease Type
5.1. Overview
5.2. Melasma
5.3. Albinism
5.4. Vitiligo
5.5. Post-Inflammatory Hyperpigmentation
5.6. Others (Solar Lentigines, Acne Vulgaris, etc.)

Chapter 6. Global Pigmentation Disorders Treatment Market, by Geography
6.1. Overview
6.2. North America Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.2.1. North America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.2.2. North America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.2.3. North America Pigmentation Disorders Treatment Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.3.1. Europe Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.3.2. Europe Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.3.3. Europe Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.4.1. Asia Pacific Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.5.1. Latin America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.5.2. Latin America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.5.3. Latin America Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa Pigmentation Disorders Treatment Market Analysis, 2016 – 2026
6.6.1. MEA Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
6.6.2. MEA Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
6.6.3. MEA Pigmentation Disorders Treatment Market, by Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. ALLERGAN PLC
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Bayer AG
7.3. Galderma S.A.
7.4. EpiPharm AG
7.5. Pierre Fabre Laboratories
7.6. La Roche-Posay Laboratoire Pharmaceutique
7.7. Obagi Cosmeceuticals LLC
7.8. RXi Pharmaceuticals Corporation
7.9. SkinCeuticals, Inc.
7.10. Vivier Pharma, Inc.

 

List of Figures

FIG. 1 Pigmentation Disorders Treatment: Research Methodology
FIG. 2 Pigmentation Disorders Treatment: Market Segmentation
FIG. 3 Global Pigmentation Disorders Treatment Market, by Treatment Type, 2017 (US$ Mn)
FIG. 4 Global Pigmentation Disorders Treatment Market, by Disease Type, 2017 (US$ Mn)
FIG. 5 Global Pigmentation Disorders Treatment Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global Pigmentation Disorders Treatment Market, by Key Players, 2017
FIG. 8 Global Topical Drugs Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 9 Global Chemical Peels Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 10 Global Microdermabrasion Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 11 Global Phototherapy Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 12 Global Laser Therapy Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 13 Global Melasma Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 14 Global Albinism Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 15 Global Vitiligo Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 16 Global Post-Inflammatory Hyperpigmentation Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 17 Global Other Disease Type Market for Pigmentation Disorders Treatment, 2016 – 2026 (US$ Mn)
FIG. 18 U.S. Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 19 Canada Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 20 U.K. Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 21 Germany Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Europe Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 23 China Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 24 Japan Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 25 Rest of Asia Pacific Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 26 Brazil Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 27 Mexico Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 28 Rest of Latin America Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 29 GCC Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest of Middle East and Africa Pigmentation Disorders Treatment Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Pigmentation Disorders Treatment Market Portraiture
TABLE 2 Global Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 4 Global Pigmentation Disorders Treatment Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
TABLE 6 North America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 7 North America Pigmentation Disorders Treatment Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
TABLE 9 Europe America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 10 Europe Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific Pigmentation Disorders Treatment Market, by Country/Region, 2015 – 2025 (US$ Mn)
TABLE 14 Latin America Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America Pigmentation Disorders Treatment Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa Pigmentation Disorders Treatment Market, by Treatment Type, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East and Africa Pigmentation Disorders Treatment Market, by Disease Type, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East and Africa Pigmentation Disorders Treatment Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 20 ALLERGAN PLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Galderma S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Epipharm AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Pierre Fabre Laboratories: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 La Roche-Posay Laboratorie Pharmaceutique: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Obagi Cosmeceuticals LLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 RXi Pharmaceuticals Corporation: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 SkinCeuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Vivier Pharma, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Frequently Asked Questions:

What is the size of Pigmentation Disorders Treatment Market?

The market for Pigmentation Disorders Treatment is expected to reach US$ 5,311.5 Mn in 2026.

What is the Pigmentation Disorders Treatment Market CAGR?

The Pigmentation Disorders Treatment market is expected to see significant CAGR growth over the coming years, at 6.9%.

What is the Forecast period considered for Pigmentation Disorders Treatment Market?

The report is forecasted from 2018-2026.

What is the base year considered for Pigmentation Disorders Treatment Market?

The base year of this report is 2017.

Who are the major players in this Market?

ALLERGAN PLC, Bayer AG, Galderma S.A., Epi Pharm AG, Pierre Fabre Laboratories are some of the major players in the global market.

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Basal Cell Carcinoma (BCC) Treatment Market

Published:
Report ID: 32698

Paroxysmal Nocturnal Hemoglobinuria Market

Published:
Report ID: 8654

Reversible Airway Diseases Treatment Market

Published:
Report ID: 32531

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN